| I. MODIFIED AGREEMENTS | |||
| Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) | Change from original agreement | Terms/Details (Date) |
| Alnylam Pharmaceuticals Inc. (ALNY) | Novartis AG (Switzerland) | Extended its RNAi collaboration for another year, taking it through October 2009 | The deal, worth up to $700M to Alnylam when it was signed in October 2005, is working on discovery, development and commercialization of RNAi therapeutics toward a certain number of Novartis-selected disease gene targets (7/16) |
| MorphoSys AG (Germany; FSE:MOR) | Boehringer Ingelheim GmbH (Germany) | Exercise of a pre-existing option to use MorphoSys's RapMAT technology as part of the existing technology transfer agreement between the companies | Beoheringer Ingelheim will have access to MorphoSys's RapMAT technology module alongside the existing installation of the company's antibody library HuCAL GOLD; MorphoSys will receive annual user fees for the RapMAT technology and for access to its HuCAL platform; financial details were not disclosed (7/9) |
| Palatin Technologies Inc. (AMEX:PTN) | AstraZeneca plc (UK) | Amended licensing deal to cover additional compounds and intellectual property | Palatin inked a $310M deal with Astra-Zeneca to develop small-molecule mel-anocortin-receptor drugs for obesity and other metabolic disorders (7/1) |
| II. TERMINATED AGREEMENTS | |||
| ARYx Therapeutics Inc. (ARYX) | Procter & Gamble Pharmaceuticals | Terminated agreement for ATI-7505 for chronic constipation and functional dyspepsia | The $435M deal was signed in 2006; P&G said it no longer fits within its criteria established two years ago (7/3) |
| Exelixis Inc. (EXEL) | GlaxoSmithKline plc (UK) | Ended six-year discovery and development collaboration | The term was over and Exelixis was satisfied that it has moved several compounds into the clinic from the collaboration; Exelixis received about $235M from GSK through the deal (6/27) |
| Labopharm Inc. (Canada; DDSS) | Recordati Ireland Ltd. (Milan:REC) | Agreement under which Labopharm reacquired the sales and marketing rights to Tradorec XL for the UK from Recordati | Labopharm is receiving a €700,000 milestone from Recordati upon termination of Recordati's rights (7/7) |
|
Notes: # The information in the chart does not cover agreements between biotech companies or agricultural agreements. * Private companies are indicated with an asterisk.Unless otherwise noted, stock symbols listed are on the Nasdaq market. AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange. | |||
